IBD and Pregnancy: Medications and Fetal Safety Guide 2026

The Scary Truth About IBD and Pregnancy

If you have Inflammatory Bowel Disease (IBD) and you are thinking about getting pregnant, you probably feel caught between two scary scenarios. On one hand, you want to protect your future baby from harmful drugs. On the other hand, you know that if your disease flares up, it hurts everyone involved. This anxiety is incredibly common, reported by nearly 70% of women with IBD planning a family.

Here is the hard truth that changes everything: uncontrolled IBD poses significantly greater risks to a pregnancy than the medications used to manage it. When we look at the data from the PIANO Registry, which tracks thousands of pregnancies globally, we see that women who stop their meds and let their disease run wild face real dangers. Active disease at the moment you conceive bumps your risk of preterm birth by 2.3 times. It increases the risk of having a baby with low birth weight by 1.8 times. Even worse, the risk of stillbirth jumps by 1.6 times compared to women whose disease is quiet. Keeping your disease in remission isn't just good for your gut health; it is the single most important thing you can do for your baby's health.

Which Drugs Are Actually Safe?

Not all pills carry the same risks, and thanks to updates like the 2024 European Crohn's and Colitis Organisation (ECCO Guidelines) standards, we have much clearer maps now. Let's break down what you need to know about the different drug classes. We aren't giving medical advice here, but rather summarizing what the experts currently agree on so you can talk to your doctor with confidence.

Aminosalicylates: Watch the Details

Drugs like mesalamine and sulfasalazine are the backbone of maintenance therapy for many people with Ulcerative Colitis. Generally, they are considered safe to take throughout pregnancy. However, there is a specific trap you need to avoid. Some older formulations of mesalamine, specifically the brand Asacol, used to contain a coating agent called dibutyl phthalate (DBP). Studies have shown this chemical can cause urogenital malformations in male babies if taken in high doses. Fortunately, modern manufacturing has largely moved away from this, but you must check with your pharmacist. Ask them to confirm your specific prescription does not contain DBP. If it uses Lialda or another DBP-free version, you are generally clear to continue.

If you are taking sulfasalazine, there is another small detail. Because this drug blocks your body's ability to absorb folic acid, you need to bump up your prenatal vitamin dose. Your doctor might recommend a higher dose of Folate supplementation to make sure your baby gets enough during development. Without this extra boost, you could be putting yourself at risk for neural tube defects simply because the medication is blocking absorption.

Biologics: The Heavy Hitters

When disease is harder to control, doctors turn to biologics. For a long time, there was huge uncertainty around these powerful drugs, but the numbers are reassuring now. The Anti-Tumor Necrosis Factor (Anti-TNF Agents) group includes drugs like Infliximab and Adalimumab. We have followed over 2,000 pregnancies exposed to these drugs in the PIANO registry. The data shows the rate of congenital anomalies is basically the same as the general population-around 2.6%. This means the medicine itself is not making bad things happen to the baby's development.

Vedolizumab is another option, though the dataset is smaller. A large study tracked over 100 pregnancies where women took this drug. There were no signs of cancer in infants followed up for a year. While there was some worry earlier about lower live birth rates, further analysis suggested that difference disappeared when the mother had active disease. Essentially, if your disease is well-controlled on Vedolizumab, it is likely safer than letting it flare.

Then there is Ustekinumab. Recent data from 681 pregnancies suggests adverse outcomes are comparable to the average US population. If you are already on this maintenance therapy and stable, staying on it is usually the preferred path over switching to something less proven.

The Red Zone: What to Never Take

There are some medications that act as absolute red flags. You cannot play games with these. Methotrexate is perhaps the most famous example. It interferes with DNA synthesis, which stops cell division. Since a growing fetus relies entirely on rapid cell division, this causes severe birth defects. The risk of major congenital malformations is estimated between 17% and 27%. That is an unacceptable risk. You need to stop methotrexate completely before becoming pregnant-usually at least three months prior. If you slip up and get pregnant while on it, contact your specialist immediately to discuss next steps.

Thalidomide is another absolute "no-go," largely banned from use anyway due to historical teratogenicity. Regarding newer drugs like JAK inhibitors (e.g., Tofacitinib), the data is sparser. While a small study of 11 pregnancies showed no immediate alarm bells, guidelines suggest stopping this drug about a week before you try to conceive just to be safe. Since there are other options that have decades of safety history (like Anti-TNFs), it makes sense to switch off the JAK inhibitor early.

Timing is Everything

How do you actually implement this? Most women think about pregnancy until they decide to try. For IBD, you need to start the conversation much earlier. Experts recommend aiming for clinical and endoscopic remission for at least three months before you start trying to conceive. Why three months? That gives your immune system time to stabilize without the chaotic swings of a flare-up.

You also need to involve a second set of eyes. A gastroenterologist knows your disease, but an obstetrician needs to know your medications. They work differently in pregnancy. For example, some providers now advise continuing anti-TNF dosing through delivery unless you have a specific reason to stop. Why? Because keeping levels stable helps prevent a flare right after birth when stress is high. However, they might adjust doses in the third trimester. High levels of infliximab in the mother cross the placenta and can stay in the baby's blood for several months. This can affect how your baby responds to vaccines later, so knowing the timeline helps pediatricians schedule shots correctly.

Breastfeeding Considerations

After delivery, the question shifts to nursing. Most IBD medications pass into breast milk in very small amounts, usually too low to hurt the infant. Sulfasalazine is a bit tricky; while the amount excreted is low, some sources suggest monitoring for rash or jaundice in the newborn, though toxicity is unlikely. Anti-TNF drugs are generally considered compatible with breastfeeding because the proteins are broken down in the baby's stomach and poorly absorbed. The consensus is that the benefits of breastfeeding usually outweigh the theoretical risks.